ReviewInternational journal of ophthalmology2023
Recent progress in N6-methyladenosine modification in ocular surface diseases.
Review in International journal of ophthalmology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- METTL3-catalyzed m6A modification of NSUN4 mediates m5C modification of SLC2A3 mRNA to regulate PDGF-BB-induced proliferation, hyaluronan production and glycolysis in human orbital fibroblasts.Journal of bioenergetics and biomembranes · 2026Article
- CD3ε of a pan T cell marker involved in mouseInternational journal of ophthalmology · 2024Article
- Characterization of NInternational journal of ophthalmology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
N6-methyladenosine (m6A) modification is a reversible process promoted by "writers", inhibited by "erasers", and processed by "readers". During the last decade, increasing emphasis has been placed on the underlying roles of m6A modification owing to their great importance in biological significance. The abnormal regulation of m6A modification will lead to aberrant cellular behavior and various diseases. Recently, studies have demonstrated that m6A modification is closely associated with the genesis and progression of ocular surface diseases (OSDs). This review focus on the role of m6A modification and research progress in OSDs including fungal keratitis, herpes simplex keratitis, immune-related keratoconjunctival diseases, pterygium, ocular chemical burns, and Graves' ophthalmopathy, which may provide new insights into and prospective applications for OSDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.